id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-0102-0009,FDA,FDA-2014-E-0102,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2015-12-28T05:00:00Z,2015,12,2015-12-28T05:00:00Z,,2015-12-28T16:18:14Z,,0,0,0900006481dd40fe
FDA-2014-E-0102-0008,FDA,FDA-2014-E-0102,"Determination of Regulatory Review Period for Purposes of Patent
Extension; Xience Xpedition Everolimus Eluting Coronary Stent
System",Notice,Determinations,2015-04-29T04:00:00Z,2015,4,2015-04-29T04:00:00Z,2015-10-27T03:59:59Z,2015-04-29T15:18:12Z,2015-09902,0,0,0900006481ac2567
FDA-2014-E-0102-0007,FDA,FDA-2014-E-0102,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-03-31T04:00:00Z,2015,3,2015-03-31T04:00:00Z,,2015-03-31T18:48:13Z,,0,0,0900006481a7eba5
FDA-2014-E-0102-0006,FDA,FDA-2014-E-0102,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2015-02-27T05:00:00Z,2015,2,2015-02-27T05:00:00Z,,2015-02-27T13:54:12Z,,0,0,0900006481a1b5db